{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T05:01:13Z","timestamp":1763269273508,"version":"3.45.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52233007"],"award-info":[{"award-number":["52233007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13346-025-01886-w","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T14:05:53Z","timestamp":1749909953000},"page":"4761-4774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["D-mannose augments targeted radioligand-immunotherapy of prostate cancer by enhancing radiosensitivity and reshaping immune microenvironment"],"prefix":"10.1007","volume":"15","author":[{"given":"Lei","family":"Tao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangtao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenghua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"1886_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1886_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG. Prostate cancer Nat Rev Dis Primers. 2021;7:9. https:\/\/doi.org\/10.1038\/s41572-020-00243-0.","journal-title":"Prostate cancer Nat Rev Dis Primers"},{"key":"1886_CR3","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s00259-024-06677-y","volume":"51","author":"S Satapathy","year":"2024","unstructured":"Satapathy S, Yadav MP, Ballal S, Sahoo RK, Bal C. [177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: A real-world study. Eur J Nucl Med Mol Imaging. 2024;51:2495\u2013503. https:\/\/doi.org\/10.1007\/s00259-024-06677-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1886_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2967\/jnumed.123.266842","volume":"65","author":"AM Tuchayi","year":"2024","unstructured":"Tuchayi AM, Yadav S, Jiang F, Kim ST, Saelee RK, Morley A, Juarez R, Lawhn-Heath C, Wang Y, de Kouchkovsky I, Hope TA. Real-world experience with 177Lu-PSMA-617 radioligand therapy after Food and Drug Administration approval. J Nucl Med. 2024;65:735. https:\/\/doi.org\/10.2967\/jnumed.123.266842.","journal-title":"J Nucl Med"},{"key":"1886_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114538","volume":"190","author":"J Sun","year":"2022","unstructured":"Sun J, Huangfu Z, Yang J, Wang G, Hu K, Gao M, Zhong Z. Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation. Adv Drug Deliv Rev. 2022;190: 114538. https:\/\/doi.org\/10.1016\/j.addr.2022.114538.","journal-title":"Adv Drug Deliv Rev"},{"key":"1886_CR6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, P\u00e9rez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"1886_CR7","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"key":"1886_CR8","doi-asserted-by":"publisher","unstructured":"Hofman M S, Emmett L, Sandhu S, Iravani A, Joshua A M, Goh J C, Pattison D A, Tan T H, Kirkwood I D, Ng S, Francis R J, Gedye C, Rutherford N K, Weickhardt A, Scott A M, Lee S T, Kwan E M, Azad A A, Ramdave S, Redfern A D, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang A Y, McJannett M M, Stockler M R, Violet J A, Williams S G, Martin A J, Davis I D, Thera P T I, the A, New Zealand U, Prostate Cancer Trials G. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"1886_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.122.264104","volume":"64","author":"S Pathmanandavel","year":"2023","unstructured":"Pathmanandavel S, Crumbaker M, Nguyen A, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Eu P, Martin AJ, Stockler MR, Joshua AM, Emmett L. The prognostic value of posttreatment (68)Ga-PSMA-11 PET\/CT and (18)F-FDG PET\/CT in metastatic castration-resistant prostate cancer treated with (177)Lu-PSMA-617 and NOX66 in a Phase I\/II trial (Lupin). J Nucl Med. 2023;64:69\u201374. https:\/\/doi.org\/10.2967\/jnumed.122.264104.","journal-title":"J Nucl Med"},{"key":"1886_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","volume":"125","author":"F Ahmad","year":"2021","unstructured":"Ahmad F, Cherukuri MK, Choyke PL. Metabolic reprogramming in prostate cancer. Br J Cancer. 2021;125:1185\u201396. https:\/\/doi.org\/10.1038\/s41416-021-01435-5.","journal-title":"Br J Cancer"},{"key":"1886_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-018-0758-7","volume":"37","author":"L Tang","year":"2018","unstructured":"Tang L, Wei F, Wu Y, He Y, Shi L, Xiong F, Gong Z, Guo C, Li X, Deng H, Cao K, Zhou M, Xiang B, Li X, Li Y, Li G, Xiong W, Zeng Z. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. 2018;37:87. https:\/\/doi.org\/10.1186\/s13046-018-0758-7.","journal-title":"J Exp Clin Cancer Res"},{"key":"1886_CR12","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cmet.2018.02.024","volume":"27","author":"T Cascone","year":"2018","unstructured":"Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. Cell Metab. 2018;27:977\u201387. https:\/\/doi.org\/10.1016\/j.cmet.2018.02.024.","journal-title":"Cell Metab"},{"key":"1886_CR13","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2326-6066.CIR-20-0111","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang X, Lu Y, Hang J, Zhang J, Zhang T, Huo Y, Liu J, Lai S, Luo D, Wang L, Hua R, Lin Y. Lactate-modulated immunosuppression of myeloid-derived suppressor cells contributes to the radioresistance of pancreatic cancer. Cancer Immunol Res. 2020;8:1440\u201351. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0111.","journal-title":"Cancer Immunol Res"},{"key":"1886_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.trecan.2022.05.005","volume":"8","author":"A Mittal","year":"2022","unstructured":"Mittal A, Nenwani M, Sarangi I, Achreja A, Lawrence TS, Nagrath D. Radiotherapy-induced metabolic hallmarks in the tumor microenvironment. Trends Cancer. 2022;8:855\u201369. https:\/\/doi.org\/10.1016\/j.trecan.2022.05.005.","journal-title":"Trends Cancer"},{"key":"1886_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202401017","volume":"36","author":"L Cao","year":"2024","unstructured":"Cao L, Yang Y, Zheng Y, Cheng W, Chen M, Wang T, Mu C, Wu M, Liu B. X-ray-triggered co-release from gold nanocluster: All-in-one nanoplatforms for cancer targeted gas and radio synergistic therapy. Adv Mater. 2024;36: e2401017. https:\/\/doi.org\/10.1002\/adma.202401017.","journal-title":"Adv Mater"},{"key":"1886_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122035","volume":"295","author":"Z Fu","year":"2023","unstructured":"Fu Z, Liu Z, Wang J, Deng L, Wang H, Tang W, Ni D. Interfering biosynthesis by nanoscale metal-organic frameworks for enhanced radiation therapy. Biomaterials. 2023;295: 122035. https:\/\/doi.org\/10.1016\/j.biomaterials.2023.122035.","journal-title":"Biomaterials"},{"key":"1886_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400297","volume":"11","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Li C, Li C, Zhou L, Tan S, Hou W, Xie C, Wang L, Shen J, Xiong W. Mitochondria-targeted nanoadjuvants induced multi-functional immune-microenvironment remodeling to sensitize tumor radio-immunotherapy. Adv Sci (Weinh). 2024;11: e2400297. https:\/\/doi.org\/10.1002\/advs.202400297.","journal-title":"Adv Sci (Weinh)"},{"key":"1886_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401394","volume":"11","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Jiang X, Yi L, Li C, Wang H, Xiong W, Li Z, Shen J. Mitochondria energy metabolism depression as novel adjuvant to sensitize radiotherapy and inhibit radiation induced-pulmonary fibrosis. Adv Sci (Weinh). 2024;11: e2401394. https:\/\/doi.org\/10.1002\/advs.202401394.","journal-title":"Adv Sci (Weinh)"},{"key":"1886_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"Ma X, Bi E, Lu Y, Su P, Huang C, Liu L, Wang Q, Yang M, Kalady MF, Qian J, Zhang A, Gupte AA, Hamilton DJ, Zheng C, Yi Q. Cholesterol induces CD8(+) T cell exhaustion in the tumor microenvironment. Cell Metab. 2019;30:143\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2019.04.002.","journal-title":"Cell Metab"},{"key":"1886_CR20","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.1038\/s41467-023-41016-z","volume":"14","author":"S Inamdar","year":"2023","unstructured":"Inamdar S, Suresh AP, Mangal JL, Ng ND, Sundem A, Wu C, Lintecum K, Thumsi A, Khodaei T, Halim M, Appel N, Jaggarapu M, Esrafili A, Yaron JR, Curtis M, Acharya AP. Rescue of dendritic cells from glycolysis inhibition improves cancer immunotherapy in mice. Nat Commun. 2023;14:5333. https:\/\/doi.org\/10.1038\/s41467-023-41016-z.","journal-title":"Nat Commun"},{"key":"1886_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","volume":"20","author":"RD Leone","year":"2020","unstructured":"Leone RD, Powell J. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20:516\u201331. https:\/\/doi.org\/10.1038\/s41568-020-0273-y.","journal-title":"Nat Rev Cancer"},{"key":"1886_CR22","doi-asserted-by":"publisher","unstructured":"Faubert B, Solmonson A, DeBerardinis R J. Metabolic reprogramming and cancer progression. Science. 2020;368:eaaw5473. https:\/\/doi.org\/10.1126\/science.aaw5473.","DOI":"10.1126\/science.aaw5473"},{"key":"1886_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40170-021-00258-5","volume":"9","author":"DL Nile","year":"2021","unstructured":"Nile DL, Rae C, Walker DJ, Waddington JC, Vincent I, Burgess K, Gaze MN, Mairs RJ, Chalmers AJ. Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells. Cancer Metab. 2021;9:24. https:\/\/doi.org\/10.1186\/s40170-021-00258-5.","journal-title":"Cancer Metab"},{"key":"1886_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188970","volume":"1878","author":"H Jin","year":"2023","unstructured":"Jin H, Liu X, Liu HX. Biological function, regulatory mechanism, and clinical application of mannose in cancer. Biochim Biophys Acta Rev Cancer. 2023;1878: 188970. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188970.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1886_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41586-018-0729-3","volume":"563","author":"PS Gonzalez","year":"2018","unstructured":"Gonzalez PS, O\u2019Prey J, Cardaci S, Barthet VJA, Sakamaki JI, Beaumatin F, Roseweir A, Gay DM, Mackay G, Malviya G, Kania E, Ritchie S, Baudot AD, Zunino B, Mrowinska A, Nixon C, Ennis D, Hoyle A, Millan D, McNeish IA, Sansom OJ, Edwards J, Ryan KM. Mannose impairs tumour growth and enhances chemotherapy. Nature. 2018;563:719\u201323. https:\/\/doi.org\/10.1038\/s41586-018-0729-3.","journal-title":"Nature"},{"key":"1886_CR26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114851119","volume":"119","author":"R Zhang","year":"2022","unstructured":"Zhang R, Yang Y, Dong W, Lin M, He J, Zhang X, Tian T, Yang Y, Chen K, Lei QY, Zhang S, Xu Y, Lv L. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proc Natl Acad Sci U S A. 2022;119: e2114851119. https:\/\/doi.org\/10.1073\/pnas.2114851119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1886_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12032-021-01552-4","volume":"38","author":"Y Yao","year":"2021","unstructured":"Yao Y, Liu W, Li J, Zhou M, Qu C, Wang K. MPI-based bioinformatic analysis and co-inhibitory therapy with mannose for oral squamous cell carcinoma. Med Oncol. 2021;38:103. https:\/\/doi.org\/10.1007\/s12032-021-01552-4.","journal-title":"Med Oncol"},{"key":"1886_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216883","volume":"591","author":"W Dong","year":"2024","unstructured":"Dong W, Lin M, Zhang R, Sun X, Li H, Liu T, Xu Y, Lv L. D-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity. Cancer Lett. 2024;591: 216883. https:\/\/doi.org\/10.1016\/j.canlet.2024.216883.","journal-title":"Cancer Lett"},{"key":"1886_CR29","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1016\/S1470-2045(17)30379-0","volume":"18","author":"MR Gill","year":"2017","unstructured":"Gill MR, Falzone N, Du Y, Vallis KA. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol. 2017;18:e414\u201323. https:\/\/doi.org\/10.1016\/S1470-2045(17)30379-0.","journal-title":"Lancet Oncol"},{"key":"1886_CR30","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jconrel.2024.09.040","volume":"375","author":"Z Huangfu","year":"2024","unstructured":"Huangfu Z, Yang J, Sun J, Xu B, Tao L, Wu J, Wang F, Wang G, Meng F, Zhong Z. PSMA and sigma-1 receptor dual-targeted peptide mediates superior radionuclide imaging and therapy of prostate cancer. J Control Release. 2024;375:767\u201375. https:\/\/doi.org\/10.1016\/j.jconrel.2024.09.040.","journal-title":"J Control Release"},{"key":"1886_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113686","volume":"382","author":"J Sun","year":"2025","unstructured":"Sun J, Yang J, Guo J, Tao L, Xu B, Wang G, Meng F, Zhong Z. Dual-targeted alpha therapy mitigates prostate cancer and boosts immune checkpoint blockade therapy. J Control Release. 2025;382: 113686. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113686.","journal-title":"J Control Release"},{"key":"1886_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.abi6378","volume":"376","author":"BD Larsen","year":"2022","unstructured":"Larsen BD, Benada J, Yung PYK, Bell RAV, Pappas G, Urban V, Ahlskog JK, Kuo TT, Janscak P, Megeney LA, Els\u00e4sser SJ, Bartek J, S\u00f8rensen CS. Cancer cells use self-inflicted DNA breaks to evade growth limits imposed by genotoxic stress. Science. 2022;376:476\u201383. https:\/\/doi.org\/10.1126\/science.abi6378.","journal-title":"Science"},{"key":"1886_CR33","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.7150\/ijbs.85893","volume":"19","author":"M Chen","year":"2023","unstructured":"Chen M, Xiao Z, Huang Z, Xue KY, Xia H, Zhou JW, Liao DY, Liang ZJ, Xie X, Wei QZ, Zhong L, Yang JK, Liu CD, Liu Y, Zhao SC. Glycine decarboxylase (GLDC) plays a crucial role in regulating energy metabolism, invasion, metastasis and immune escape for prostate cancer. Int J Biol Sci. 2023;19:4726\u201343. https:\/\/doi.org\/10.7150\/ijbs.85893.","journal-title":"Int J Biol Sci"},{"key":"1886_CR34","doi-asserted-by":"publisher","first-page":"29902","DOI":"10.1021\/acsami.4c04952","volume":"16","author":"J Yang","year":"2024","unstructured":"Yang J, Chu M, Zhang Y, Qian J, Liu J, Wang M, Qiang Z, Ren J. Mito-specific nutri-hijacker synergizing mitochondrial metabolism and glycolysis intervention for enhanced antitumor bioenergetic therapy. ACS Appl Mater Interfaces. 2024;16:29902\u201316. https:\/\/doi.org\/10.1021\/acsami.4c04952.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1886_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13046-019-1214-z","volume":"38","author":"J Lin","year":"2019","unstructured":"Lin J, Xia L, Liang J, Han Y, Wang H, Oyang L, Tan S, Tian Y, Rao S, Chen X, Tang Y, Su M, Luo X, Wang Y, Wang H, Zhou Y, Liao Q. The roles of glucose metabolic reprogramming in chemo- and radio-resistance. J Exp Clin Cancer Res. 2019;38:218. https:\/\/doi.org\/10.1186\/s13046-019-1214-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"1886_CR36","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00262-020-02606-8","volume":"69","author":"J Rouanet","year":"2020","unstructured":"Rouanet J, Benboubker V, Akil H, Hennino A, Auzeloux P, Besse S, Pereira B, Delorme S, Mansard S, D\u2019Incan M, Degoul F, Rouzaire PO. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy. Cancer Immunol Immunother. 2020;69:2075\u201388. https:\/\/doi.org\/10.1007\/s00262-020-02606-8.","journal-title":"Cancer Immunol Immunother"},{"key":"1886_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188704","volume":"1877","author":"MI Koukourakis","year":"2022","unstructured":"Koukourakis MI, Giatromanolaki A. Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisal of therapeutic principles. Biochim Biophys Acta Rev Cancer. 2022;1877: 188704. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188704.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1886_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.11.003","author":"Y Qiu","year":"2024","unstructured":"Qiu Y, Su Y, Xie E, Cheng H, Du J, Xu Y, Pan X, Wang Z, Chen DG, Zhu H, Greenberg PD, Li G. Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. Cancer Cell. 2024. https:\/\/doi.org\/10.1016\/j.ccell.2024.11.003.","journal-title":"Cancer Cell"},{"key":"1886_CR39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41577-018-0009-3","volume":"18","author":"P Golstein","year":"2018","unstructured":"Golstein P, Griffiths GM. An early history of T cell-mediated cytotoxicity. Nat Rev Immunol. 2018;18:527\u201335. https:\/\/doi.org\/10.1038\/s41577-018-0009-3.","journal-title":"Nat Rev Immunol"},{"key":"1886_CR40","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41590-018-0109-z","volume":"19","author":"M Hons","year":"2018","unstructured":"Hons M, Kopf A, Hauschild R, Leithner A, Gaertner F, Abe J, Renkawitz J, Stein JV, Sixt M. Chemokines and integrins independently tune actin flow and substrate friction during intranodal migration of T cells. Nat Immunol. 2018;19:606\u201316. https:\/\/doi.org\/10.1038\/s41590-018-0109-z.","journal-title":"Nat Immunol"},{"key":"1886_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12951-024-02496-3","volume":"22","author":"Z Deng","year":"2024","unstructured":"Deng Z, Li B, Yang M, Lu L, Shi X, Lovell JF, Zeng X, Hu W, Jin H. Irradiated microparticles suppress prostate cancer by tumor microenvironment reprogramming and ferroptosis. J Nanobiotechnology. 2024;22:225. https:\/\/doi.org\/10.1186\/s12951-024-02496-3.","journal-title":"J Nanobiotechnology"},{"key":"1886_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666231","volume":"12","author":"AM Amitrano","year":"2021","unstructured":"Amitrano AM, Berry BJ, Lim K, Kim KD, Waugh RE, Wojtovich AP, Kim M. Optical control of CD8(+) T cell metabolism and effector functions. Front Immunol. 2021;12: 666231. https:\/\/doi.org\/10.3389\/fimmu.2021.666231.","journal-title":"Front Immunol"},{"key":"1886_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0578-4","volume":"11","author":"X Li","year":"2018","unstructured":"Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11:1\u201326. https:\/\/doi.org\/10.1186\/s13045-018-0578-4.","journal-title":"J Hematol Oncol"},{"key":"1886_CR44","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao L, Pang Y, Zhou Y, Chen J, Fu H, Guo W, Xu W, Xue X, Su G, Sun L, Wu H, Zhang J, Wang Z, Lin Q, Chen X, Chen H. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. Signal Transduct Target Ther. 2024;9:142. https:\/\/doi.org\/10.1038\/s41392-024-01853-w.","journal-title":"Signal Transduct Target Ther"},{"key":"1886_CR45","doi-asserted-by":"publisher","unstructured":"Shi J, Gao H, Wu Y, Luo C, Yang G, Luo Q, Jia B, Han C, Liu Z, Wang F. Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade. Eur J Nucl Med Mol Imaging. 2024:1\u201315. https:\/\/doi.org\/10.1007\/s00259-024-06962-w.","DOI":"10.1007\/s00259-024-06962-w"},{"key":"1886_CR46","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41585-024-00924-5","volume":"21","author":"S Lunj","year":"2024","unstructured":"Lunj S, Smith TAD, Reeves KJ, Currell F, Honeychurch J, Hoskin P, Choudhury A. Immune effects of alpha and beta radionuclides in metastatic prostate cancer. Nat Rev Urol. 2024;21:651\u201361. https:\/\/doi.org\/10.1038\/s41585-024-00924-5.","journal-title":"Nat Rev Urol"},{"key":"1886_CR47","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1158\/2326-6066.Cir-18-0633","volume":"7","author":"M Mondini","year":"2019","unstructured":"Mondini M, Loyher PL, Hamon P, de Thor\u00e9 MG, Laviron M, Berthelot K, Cl\u00e9menson C, Salomon BL, Combadi\u00e8re C, Deutsch E, Boissonnas A. CCR2-dependent recruitment of Tregs and monocytes following radiotherapy is associated with tnf\u03b1-mediated resistance. Cancer Immunol Res. 2019;7:376\u201387. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0633.","journal-title":"Cancer Immunol Res"},{"key":"1886_CR48","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/2326-6066.Cir-21-1105","volume":"10","author":"C Jim\u00e9nez-Cortegana","year":"2022","unstructured":"Jim\u00e9nez-Cortegana C, Galassi C, Klapp V, Gabrilovich D, Galluzzi L. Myeloid-derived suppressor cells and radiotherapy. Cancer Immunol Res. 2022;10:545\u201357. https:\/\/doi.org\/10.1158\/2326-6066.Cir-21-1105.","journal-title":"Cancer Immunol Res"},{"key":"1886_CR49","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","volume":"186","author":"DJ Kloosterman","year":"2023","unstructured":"Kloosterman DJ, Akkari L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell. 2023;186:1627\u201351. https:\/\/doi.org\/10.1016\/j.cell.2023.02.020.","journal-title":"Cell"},{"key":"1886_CR50","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2023.04.019","volume":"41","author":"L Wang","year":"2023","unstructured":"Wang L, Dou X, Chen S, Yu X, Huang X, Zhang L, Chen Y, Wang J, Yang K, Bugno J, Pitroda S, Ding X, Piffko A, Si W, Chen C, Jiang H, Zhou B, Chmura SJ, Luo C, Liang HL, He C, Weichselbaum RR. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023;41:1294\u2013308. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.019.","journal-title":"Cancer Cell"},{"key":"1886_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc1252","volume":"4","author":"G Dranoff","year":"2004","unstructured":"Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11\u201322. https:\/\/doi.org\/10.1038\/nrc1252.","journal-title":"Nat Rev Cancer"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01886-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01886-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01886-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T05:00:40Z","timestamp":1763269240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01886-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1886"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01886-w","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"type":"print","value":"2190-393X"},{"type":"electronic","value":"2190-3948"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"19 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}